Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cyclacel Pharmaceuti (CYCCP)

Cyclacel Pharmaceuti (CYCCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 43 K
  • Annual Income, $ -11,212 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.07 +24.08%
on 08/13/25
7.40 -31.76%
on 08/14/25
+0.72 (+16.63%)
since 08/08/25
3-Month
4.04 +25.00%
on 08/06/25
7.40 -31.76%
on 08/14/25
-0.65 (-11.40%)
since 06/11/25
52-Week
3.29 +53.50%
on 04/08/25
17.00 -70.29%
on 03/04/25
-2.71 (-34.92%)
since 09/11/24

Most Recent Stories

More News
Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) (“Bio Green Med” or the “Company”), a company engaged in diversified industries,...

CYCCP : 5.05 (-4.36%)
BGMS : 1.4400 (-4.00%)
BGMSP : 3.40 (-8.85%)
CYCC : 6.37 (-5.98%)
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

         - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals,...

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
Cyclacel Pharmaceuticals Announces Stock Split

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar